Abstract
Background: Local control remains an important issue in the management of large soft tissue sarcomas. Radiation is the main adjuvant to surgery for local therapy of sarcomas, but it requires relatively high doses, hitherto considered prohibitive in areas such as the retroperitoneum. We developed a preoperative treatment approach to large soft tissue sarcomas that would deliver a high total dose of radiation administered in conjunction with the halogenated pyrimidine radiosensitizer idoxuridine (IdUrd).
Methods: Thirty-seven patients with large sarcomas of the head and neck, mediastinum, retroperitoneum, or extremity received three or five cycles of sequential IdUrd infusion (1000–1600 mg/m2/d×5 d) alternating weekly with twice daily radiation (125–150 cGy per dose) and were then evaluated for resection. The delivered preoperative radiation dose was up to 6250 to 7500 cGy.
Results: Five patients (14%) had a partial response to preoperative therapy, and 28 of 37 patients underwent successful resection. There were no intra- or postoperative deaths. Local control was achieved in 19 of 28 resected patients, but in only 1 of 6 patients who remained unresectable despite therapy. With a median follow-up of 5.8 years, 28% of patients are alive with no evidence of disease, 17% are alive with disease, and 53% have died of their disease.
Conclusions: Using the dose and schedule we employed, resection of large soft tissue sarcomas was possible after high-dose radiation delivered in conjunction with IdUrd. Although local control was acceptable, the high rate of distant failure represents a limitation of any local approach to the treatment of large soft tissue sarcomas and suggests the need for integration of this approach with an effective systemic therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Emrich LJ, Ruka W, Driscoll DL, Karakousis CP. The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas.J Clin Epidemiol 1989;42:105–10.
Rööser B, Gustafson P, Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma?Cancer 1990:65:1727–9.
Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage M0 soft tissue sarcoma.J Clin Oncol 1988;6:854–62.
Eilbert F, Eckardt J, Rosen G, Forscher C, Selch M, Fu YS. Preoperative therapy for soft tissue sarcoma.Hematol Oncol Clin North Am 1995;9:817–23.
Glenn J, Sindelar WF, Kinsella T, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum.Surgery 1985;97:316–25.
Glenn J, Kinsella T, Glatstein E, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk.Cancer 1985;55:1206–14.
Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ. Enhancement of X-ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.Int J Radiat Oncol Biol Phys 1987;13:733–9.
McGinn CJ, Kinsella TJ. The clinical rationale for S-phase radio-sensitization in human tumors.Curr Probl Cancer 1993;17:275–321.
Kaplan HS. Radiobiology's contribution to radiotherapy: promise or mirage?Radiat Res 1970;43:460–76.
Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation.Cancer 1991;67:572–76.
Epstein AH, Lebovics RS, Goffman T, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.J Natl Cancer Inst 1994;86:1775–80.
Ponz de Leon M, Roncucci L, Di Donato P, et al. Pattern of epithelial cell proliferation in colorectal mucosa of normal subjects and of patients with adenomatous polyps or cancer of the large bowel.Cancer Res 1988;48:4121–6.
Lawrence TS, Davis MA, Maybaum J, et al. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.Cancer Res 1992;52:3698–704.
Lawrence TS, Davis MA, Stetson PL, Maybaum J, Ensminger WD. Kinetics of bromodeoxyuridine elimination from human colon cancer cellsin vitro andin vivo.Cancer Res 1994;54:2964–8.
Iliakis G, Kurtzman S, Pantelias G, Okayasu R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing.Radiat Res 1989;119:286–304.
Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The effect of single versus double stranded substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.Radiat Res 1991;123:192–8.
Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.Int J Radiat Oncol Biol Phys 1990;18:1393–8.
Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS. Preoperative radiation therapy and idoxuridine for large retroperitoneal sarcomas.Int J Radiat Oncol Biol Phys 1995;31:87–92.
Elias AD, Antmann KH. Adjuvant chemotherapy for soft-tissue sarcomas: a critical appraisal.Semin Surg Oncol 1988;4:59–65.
Urtasun RC, Kinsella TJ, Farnan N, Del Rowe JD, Lester SG, Fulton DS. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study.Int J Radiat Oncol Biol Phys 1996;36:1163–7.
Yang RS, Lane JM, Eilber FR, et al. High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis.Cancer 1995;76:1398–405.
Casper ES, Gaynor JJ, Harrison LB, Panicek DM, Hajdu SI, Brennan MF. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma.Cancer 1994;73:1644–51.
Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL. Resectability and survival in retroperitoneal sarcomas.Ann Surg Oncol 1996;3:150–8.
Sindelar WF, Kinsella TJ, Chen PW, Delaney TF, Tepper JE, Rosenberg SA, Glatstein E. Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized clinical trial.Arch Surg 1993;128:402–10.
Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials.Br J Cancer 1995;72:469–75.
Russo A, DeGraff W, Kinsella TJ, Gamson J, Glatstein E, Mitchell JB. Potentiation of chemotherapy cytotoxicity following iododeoxyuridine incorporation in Chinese hamster cells.Int J Radiat Oncol Biol Phys 1986;12:1371–4.
Chi KH, Kunugi KA, Kinsella TJ. Iododeoxyuridine chemosensitization of cisdiamminedichloroplatinum(II) in human bladder cancer cells.Cancer Res 1994;54:2701–6.
Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.Cancer Res 1993;53:1293–6.
Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS, Romsdahl MM. Preoperative chemotherapy for soft-tissue sarcomas of the extremities.Ann Surg 1990;211:476–81.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sondak, V.K., Robertson, J.M., Sussman, J.J. et al. Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up. Annals of Surgical Oncology 5, 106–112 (1998). https://doi.org/10.1007/BF02303842
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303842